Cellular Intelligence, a rapidly emerging biotech firm previously known as Somite AI, has secured global rights to a pioneering clinical-stage…
Read More
Sai Life Sciences Galvanizes Early-Stage Biotech Innovation with Landmark 2026 Pitch Day in Boston
Sai Life Sciences, a global contract research, development, and manufacturing organization (CRDMO), recently convened its highly anticipated Biotech Pitch Day…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The dramatic emergence of GLP-1 receptor agonists has undeniably revolutionized the landscape of obesity treatment, driving pharmaceutical giants like Eli…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The fiscal year 2025 closed with a dramatic reshuffling at the pinnacle of the pharmaceutical industry’s sales leaderboard, signaling profound…
Read More
Insilico Medicine and Eli Lilly Forge Potentially $2.75 Billion AI-Driven Drug Discovery Alliance, Signaling a New Era of Pharmaceutical Innovation
On March 29, Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, announced a landmark collaboration with…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
Amazon Web Services (AWS) has announced the launch of Amazon Bio Discovery, a groundbreaking application poised to revolutionize drug discovery…
Read More
How Immuto Scientific Pairs AI and Mass Spec for a Step Change in Protein Structure Throughput
Immuto Scientific, a pioneering biotechnology firm co-founded in 2018 by electrical engineers Faraz A. Choudhury, Ph.D. (CEO), and Daniel Benjamin,…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently riding an unprecedented wave of success fueled by its GLP-1 franchise, has announced its intent…
Read More
Rethinking evidence generation for ultra-rare diseases
Developing treatments for the approximately 7,000 known rare diseases, particularly the subset classified as ultra-rare, presents profound and often insurmountable…
Read MoreYOU MAY HAVE MISSED
